secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK:        0000879407
Form:       8-K
Filed at:   2025-11-25T23:59:59+00:00
Accession:  0000879407-25-000027
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arrowhead FY2025 revenue $829M on milestones; FDA approves first drug REDEMPLO
------------------------------------------------------------------------------

- Revenue $829.4M in FY2025, up from $3.6M, driven by Novartis and Sarepta milestone payments.
- FDA approved REDEMPLO (plozasiran) for FCS—first approved siRNA for the rare disease; self-administered quarterly.
- Novartis licensing agreement for ARO-SNCA: $200M upfront, up to $2B milestones, low double-digit royalties.
- Sarepta paid $300M milestones; $100M settled with cash and Arrowhead stock buyback at $18.79 per share.
- Net loss attributable to Arrowhead: ($1.6M) vs ($599M) prior year; cash resources $919.4M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879407/000087940725000027/0000879407-25-000027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879407/000087940725000027/arwr-20251125.htm
  HTML page:      https://secwatch.observer/filing/0000879407-25-000027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer